10:40 AM EDT, 09/10/2024 (MT Newswires) -- Jasper Therapeutics ( JSPR ) said Tuesday that Health Canada has cleared its clinical trial application for a phase 1b/2a asthma challenge study assessing briquilimab, an antibody therapy for mast cell-driven diseases.

The phase 1b/2a asthma study is expected to enroll 30 patients across 10 sites in Canada and the European Union, aiming to validate briquilimab's efficacy, with dosing beginning in Q4 and results expected in H2 2025, the company said.

The biotechnology company also said its c-Kit Mouse model has received a registered trademark from the US Patent and Trademark Office for its ability to test c-Kit or CD117 inhibitors in various diseases.

Price: 18.92, Change: -0.38, Percent Change: -1.97